AlphaNooner by AdvisorShares

What leads someone to consider psychedelic medicine, and what changes their mind about it? Navy veteran Graham Ginn joins AlphaNooner to share how childhood trauma, a mental health crisis, and a later cancer diagnosis shaped his journey from skepticism to psychedelic advocacy. Ahead of Veterans Day, the conversation explores how veterans are helping change public perceptions of psychedelics, while...

Is the AI bubble starting to burst? As investors question soaring tech valuations, massive AI infrastructure spending, and the debt financing the boom, Chris Irons of QTR's Fringe Finance joins AlphaNooner to discuss the risks building beneath the stock market rally. From CoreWeave and the AI trade to Federal Reserve policy, credit markets, and the potential for a broader market correction, Chris...

Cannabis won at the ballot box. Can cannabis stocks win on Wall Street? Following the 2026 midterm elections, Todd Harrison joins AlphaNooner to examine what the results could mean for U.S. cannabis legalization, marijuana rescheduling, and the investment outlook for cannabis stocks. From emerging state markets and federal reform to corporate earnings and industry consolidation, Todd breaks down t...

Does Election Day change the outlook for cannabis? And did investors overreact to the latest news in psychedelic biotech? Dan Ahrens joins Mackenzie Peterson on AlphaNooner to explain why he's watching the cannabis rescheduling process more closely than the balance of power in Congress. Plus, he breaks down the psychedelic stock selloff following Usona Institute's psilocybin announcement and why h...

Are investors overlooking boring stocks while the market chases AI? Eddy Elfenbein joins AlphaNooner to talk about the bond market, Federal Reserve policy, the excitement surrounding AI, and the investment case for less glamorous businesses. Eddy shares how he evaluates companies, identifies risks, and separates market narratives from business fundamentals. In this episode, we discuss: what earnin...

Companies are spending billions buying back their own shares, but not all stock buybacks create value for investors. What separates a smart share repurchase from a company simply spending cash? Minyi Chen joins AlphaNooner to explore the stock buyback boom, what repurchase activity reveals about corporate confidence, and where investors might find opportunities heading into earnings season. In thi...

How do short sellers identify vulnerable companies, even when the broader stock market is rising? Veteran short seller Brad Lamensdorf joins AlphaNooner to explain the warning signs he watches, from aggressive accounting and weakening cash flow to valuations that depend on growth companies may struggle to deliver. We discuss why he favors shorting individual companies over broad market indexes; ho...

How is the cannabis investment thesis evolving as investors await the next step in federal rescheduling? Sam Armenia, Director of Capital Markets at Vireo Growth, joins AlphaNooner to discuss regulatory catalysts, institutional investor interest, and the business fundamentals shaping the sector. Ahead of the October 21 deadline in the rescheduling process, we explore: his reading of the DEA's brie...

Is Canadian cannabis entering a new phase of growth, and what separates the companies positioned to succeed? Cannara Biotech (TSX: LOVE | OTCQX: LOVFF) COO Niko Sosiak joins AdvisorShares AlphaNooner to discuss the outlook for Canadian cannabis stocks, Cannara's competitive advantage in Québec, and its strategy for scaling profitably. We explore the company's expanded $34 million supply agreement...

Are cannabis stocks approaching a turning point, or is there more pain ahead? Investor Todd Harrison joins AlphaNooner to discuss the selloff, the potential for a contrarian opportunity, and what could bring investors back to one of the market’s most beaten-down sectors. From federal cannabis rescheduling and institutional capital to individual stock opportunities, Todd shares his perspective on w...

Hirsh Jain, founder of Ananda Strategy and newly appointed board member of LEEF Brands, joins AlphaNooner to look at how the 2026 midterms could reshape the cannabis policy map heading into 2027. We dig into Pennsylvania and the legislative path for adult-use cannabis, what changes in Texas, Wisconsin and Iowa could mean for reform efforts next year, and why the margin on Massachusetts' cannabis r...

AdvisorShares CEO Noah Hamman joins Mackenzie Peterson for a Friday AlphaNooner recap of the biggest market and investing stories of the week. From interest rates and the latest moves in stocks to AI, cannabis, and other investment themes making headlines, they break down what mattered, what may be getting overlooked, and what investors should be watching next. AlphaNooner by AdvisorShares brings...

High Tide (NASDAQ: HITI) CEO and founder Raj Grover joins AlphaNooner to discuss the company's growth strategy, Canna Cabana's membership-driven retail model and what could drive HITI's next phase of growth. High Tide is approaching an $800 million annual revenue run rate, with 2.73 million Cabana Club members and a growing international presence. Grover breaks down how the company is turning reve...

What's leading the market right now-and where could relative strength be shifting? In this episode of AlphaNooner, Mackenzie Peterson of AdvisorShares is joined by Ian Saunders, Head of Research at Nasdaq Dorsey Wright, to break down the latest market signals, leadership trends, and momentum indicators investors are watching. AlphaNooner by AdvisorShares brings you timely conversations with invest...

Todd Harrison, Founding Partner and CIO of CB1 Capital, joins AlphaNooner host Mackenzie Peterson to break down the state of cannabis investing and what investors should be watching now. They discuss Trulieve's recent index inclusion and what it could signal for institutional access, the latest developments around federal cannabis rescheduling, recent cannabis earnings, and the catalysts that coul...

What investment themes should investors be watching now? AdvisorShares' Dan Ahrens breaks down the investment themes he believes deserve attention today, including artificial intelligence and infrastructure, U.S. cannabis, psychedelic biotech, and other emerging areas of the market. Dan discusses what is driving these themes, where the investment opportunities may be developing, and what financial...

Chris Irons, publisher of Quoth the Raven (QTR), joins AlphaNooner to discuss the skeptical, contrarian approach he brings to markets. From the AI boom and higher rates to where consensus could be getting ahead of itself, Chris breaks down what he's watching, what he's questioning, and where he still sees opportunity. This conversation was pre-recorded on September 17, 2026. AlphaNooner by Advisor...

Jushi Chief Strategy Officer Trent Woloveck joins Mackenzie Peterson to discuss the evolving U.S. cannabis landscape, continued state-level movement, the federal policy picture, and what investors should be watching as the 2026 midterms approach. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, inve...

Crossing Wall Street's Eddy Elfenbein joins AlphaNooner for his latest take on the market, including rates, valuations, market leadership, and the individual stocks catching his attention. Plus, where he's finding quality and opportunity as investors head into the final stretch of 2026. AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio manag...

John Lewis of Nasdaq Dorsey Wright explains what relative strength is signaling across international stocks and global markets. He discusses where market leadership is emerging, how geopolitical uncertainty is affecting international investing, and how trend-following strategies can help investors identify strength without trying to predict the next headline. AlphaNooner by AdvisorShares brings yo...

Dan Ahrens joins AlphaNooner live from Future Proof Festival in Huntington Beach to break down the themes investors are watching across cannabis, psychedelics, biotech, and the AI buildout. What's driving attention now, where catalysts could emerge, and which trends could matter for investors through year-end? AlphaNooner by AdvisorShares brings you timely conversations with investors, market stra...

AdvisorShares CEO Noah Hamman walks through a set of market charts worth watching, from S&P 500 earnings per share and the role of inflation to how long bull and bear markets have historically lasted. Noah also compares buffered and options-based hedging strategies designed to protect against large market drawdowns and discusses the tradeoffs investors should understand. AlphaNooner by Advisor...

Todd Harrison joins Noah Hamman on AlphaNooner to examine where the cannabis market stands today, the catalysts that could reshape the sector, and where investors may find opportunity. They discuss the evolving regulatory landscape, industry fundamentals and the key developments that could drive cannabis stocks from here. AlphaNooner by AdvisorShares brings you timely conversations with investors,...

Dan Ahrens joins AlphaNooner on the move for a quick post-Labor Day look at what could move markets this week. We cover the latest in psychedelics, including Eli Lilly's deal for Beckley and what big pharma M&A could signal for the space, plus the cannabis sector outlook and consolidation, including recent developments at Curaleaf. Chapters 0:00 Welcome and introductions 1:09 Psychedelics mark...

Noah Hamman joins AlphaNooner to break down what investors should take away from the week, from shifting Fed expectations and a stronger-than-expected jobs report to moves in rates, oil, and equities, plus what could matter most for markets next week. Chapters 0:00 Market recap and intro 2:08 Economic outlook and jobs 4:00 The impact of GLP-1 drugs 9:05 Portfolio management strategy 11:59 Cannabis...